Titanium surfaces immobilized with the major antimicrobial fragment FK-16 of human cathelicidin LL-37 are potent against multiple antibiotic-resistant bacteria.
Mishra. Biswajit B; Wang. Guangshun G
Key Findings
- FK-16 can be covalently attached to titanium surfaces
- The FK-16‑coated titanium kills all major ESKAPE pathogens and blocks S. aureus and E. coli adhesion
- FK-16 is cheaper to synthesize than full LL-37 and more broadly active than the shorter KR-12
Practical Outcomes
- While not a direct supplement, the study shows FK-16 is a promising, cost‑effective antimicrobial coating for medical implants and other surfaces. Biohackers interested in anti‑infection technologies could watch for future DIY or commercial products using this peptide for wound dressings or device coatings.
Summary
Scientists stuck a short piece of the human antimicrobial protein LL-37, called FK-16, onto titanium metal and found it kills a wide range of tough, drug‑resistant bacteria and stops them from sticking and forming biofilms. This works better than the full‑length LL-37 and is cheaper to make, but it’s a surface coating, not a pill you can take.
Abstract
Infections on implanted medical devices are a challenging problem, especially when bacteria form difficult-to-treat biofilms. Antimicrobial peptides are considered to be a solution due to their potency against antibiotic-resistant superbugs. Previously, the authors' laboratory demonstrated the prevention of staphylococcal biofilm formation in an animal catheter model by injecting merecidin (formerly known as 17BIPHE2), a peptide engineered based on the only human cathelicidin. This study documents an alternative solution via covalent immobilization of FK-16, amino acid sequence FKRIVQRIKDFLRNLV-amide, which corresponds to the major antimicrobial region (residues 17-32) of LL-37. FK-16 is superior to the longer peptide LL-37 in terms of synthesis cost and the shorter peptide KR-12 in terms of activity spectrum. Indeed, the FK16-coated titanium surface showed a broad-spectrum activity against the ESKAPE pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. It also demonstrated anti-adhesion and biofilm inhibition capabilities against both S. aureus and E. coli.
Study Information
pubmed
2017
2017-07-04T00:00:00.000Z
10.1080/08927014.2017.1332186
52
48